Snowflake Analysts Remain Overweight: Potential Growth Despite Iceberg Adoption Concerns
Piper Sandler analyst attended Virtual Iceberg Summit with tech giants. Snowflake seen as having potential drag on growth, but threat may be overstated.
Dow Jones Hits 40,000, Chinese Tech Stocks Jump To 15-Month Highs, Bloodbath On Meme Stocks: What’s Driving Markets Thursday?
U.S. major stock indices climbed higher on Thursday morning, with the Dow Jones Industrial Average achieving a historic milestone by surpassing 40,000 points.
SharkNinja Emerges As A Strong Buy: Analyst Forecasts Growth Amid Strategic Innovations
BofA Securities' Alexander Perry initiated coverage on SharkNinja with a Buy rating and a $90.00 price target. Perry highlighted the company's robust growth potential, driven by its data-driven innovation and market expansion. SharkNinja's plans to launch 25 new products annually, along with expanding shelf space at major retailers like Amazon, Walmart, and Costco, are expected to bolster its market share.
Nvidia Set for Major Growth with Increased Data Center Spending and Expanding AI Demand, Analysts Say
Wedbush's Matt Bryson reiterated Outperform rating & $1,000 price target for Nvidia, citing robust demand for HBM & SSDs. Piper Sandler's Harsh Kumar maintained Overweight rating & $1,050 PT, expecting another strong quarter. Citi's Atif Malik predicts in-line Q1 sales & higher Q2 sales. All analysts bullish on Nvidia's growth potential.
Reddit Reintroduces Award Program: What It Could Mean For Future Monetization Prospects
Reddit's award program is relaunched to monetize platform, amid debate among users about its benefits and management.
‘Big Short’ Investor Michael Burry Bets Heavy On Gold, Renewable Energy Stocks, Exits Amazon, Alphabet
Michael Burry, famous for predicting 2008 crisis, made headlines with his latest 13F filing. He shifted towards commodities & renewable energy and decreased holdings in tech giants.
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Boeing Stock Takes Off After US Aviation Bill Passes, But Possible Turbulence Ahead With Legal Uncertainties
Boeing faces regulatory changes, legal challenges, and mixed technical signals. While an aviation bill offers hope, DOJ's warning adds uncertainty.
FDA Approves Expanded Use Of Bristol Myers Squibb’s Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.
AMC Entertainment: A ‘Dead Company Walking,’ Says Bear Cave Report
Report questions AMC's financial health & recent stock movements. Social media influencers have played a role but questionable position unlikely to see sustained gains.